Replies to post #6430 on CytoSorbents Corporation (CTSO)

[Murph1953]

Can CAR-T Therapy Live Up To The Biotech IPO Hype?

"Quenneville added that another reason for the upturn in optimism is greater confidence that doctors can manage CAR-T therapy's most alarming side effect, cytokine-release syndrome. Cytokines are chemical messengers produced by T cells which, when suddenly released en masse via a big T-cell infusion, can bring on high fever and a drop in blood pressure. In fact, in an earlier study two patients died of this syndrome. However, since then physicians have figured out that they can manage this problem with strong anti-inflammatory drugs, such as Amgen's Enbrel.

http://news.investors.com/012615-736198-cancer-car-t-therapy-drives-hot-biotech-ipos.htm?ven=yahoocp,yahoo&src=aurlled&p=2